Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention

Open access
Rad, Roland, Cadiñanos, Juan, Rad, Lena, Varela, Ignacio, Strong, Alexander, Kriegl, Lydia, Constantino-Casas, Fernando, Eser, Stefan, Hieber, Maren, Seidler, Barbara, Price, Stacey, Fraga, Mario F., Calvanese, Vincenzo, Hoffman, Gary, Ponstingl, Hannes, Schneider, Günter, Yusa, Kosuke, Grove, Carolyn, Schmid, Roland M., Wang, Wei, Vassiliou, George, Kirchner, Thomas, McDermott, Ultan, Liu, Pentao, Saur, Dieter, Bradley, Allan·2013·Cancer Cell

Abstract

We show that BRAF(V600E) initiates an alternative pathway to colorectal cancer (CRC), which progresses through a hyperplasia/adenoma/carcinoma sequence. This pathway underlies significant subsets of CRCs with distinctive pathomorphologic/genetic/epidemiologic/clinical characteristics. Genetic and functional analyses in mice revealed a series of stage-specific molecular alterations driving different phases of tumor evolution and uncovered mechanisms underlying this stage specificity. We further demonstrate dose-dependent effects of oncogenic signaling, with physiologic Braf(V600E) expression being sufficient for hyperplasia induction, but later stage intensified Mapk-signaling driving both tumor progression and activation of intrinsic tumor suppression. Such phenomena explain, for example, the inability of p53 to restrain tumor initiation as well as its importance in invasiveness control, and the late stage specificity of its somatic mutation. Finally, systematic drug screening revealed sensitivity of this CRC subtype to targeted therapeutics, including Mek or combinatorial PI3K/Braf inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2013.05.014

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 216

Metadata

Authors
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., Price, S., Fraga, M. F., Calvanese, V., Hoffman, G., Ponstingl, H., Schneider, G., Yusa, K., Grove, C., Schmid, R. M., Wang, W., Vassiliou, G., Kirchner, T., McDermott, U., Liu, P., Saur, D., & Bradley, A.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2013-07
Volume
24
Issue
1
Pages
15-29
ISSN
1535-6108 (ISSN-L)
OpenAlex
W1981284988
Cited by
216
References
16
FWCI
9.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention. https://app.cochat.ai/papers/10.1016/j.ccr.2013.05.014
The paper
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., Price, S., Fraga, M. F., Calvanese, V., Hoffman, G., Ponstingl, H., Schneider, G., Yusa, K., Grove, C., Schmid, R. M., . . . Bradley, A. (2013). A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention. Cancer Cell. https://doi.org/10.1016/j.ccr.2013.05.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.